Me072-2007.qxd

REVIEW ARTICLE
Introduction Into the Diagnostics
and Treatment of Premature
Ejaculation
Michael J. Mathers, Jan Schmitges, Theodor Klotz, Frank Sommer SUMMARY
Introduction: Premature ejaculation (PE) is a subjective experience characterized by a short
intravaginal ejaculatory latency time and decreased ejaculatory control. The prevalence of
premature ejaculation is approximately 25%. The etiology is unknown and there is no causal
treatment. The significant role of serotonin during ejaculation is currently being widely discussed.
Besides behavioural treatments, specific serotonin reuptake inhibitors (SSRIs) as well as
phosphodiesterase 5 inhibitors are being used with success. Methods: Selective literature review
using PubMed with the keywords premature ejaculation, prevalence, etiology, diagnostics,
therapy. Results: A thorough sexual history is mandatory in order to evaluate the potential causes
of PE. Although the exact etiology of PE is not fully understood it is becoming increasingly clear
that this condition has a neurophysiological, psychogenic, and psychological element, with
probable serotonin involvement. Effective treatment requires a thorough understanding of the
underlying pathophysiology. Besides psychotherapy there are effective treatments, which can
significantly improve the patient's sexual quality of life. Dtsch Arztebl 2007; 104(50): A 3475–80
Key words: sexual medicine, premature ejaculation, ejaculation control, treatment, serotonin,
psychotherapy
P remature ejaculation is the most common problem affecting sexual function in men
(1–3) and is insufficiently understood. It is subject to cultural and socioeconomic influences, which makes an exact definition difficult. Difficulties with the definition anddivergent study designs hamper the collection of prevalence data and are the cause for thewide spread in the literature (1–3). Often, premature ejaculation is regarded as a primarilypsychoreactive problem. Neurobiological components and optional drug treatment areoften not being considered. Objectives and methods
This article presents an overview of the diagnostic and therapeutic options for premature
ejaculation. Particular attention has been paid to the difficulty of finding a definition and to
prevalence, etiology, risk factors, diagnostics, and therapy. The literature search was
performed on PubMed in March 2007, without a time limit and using the search terms
premature ejaculation, prevalence, etiology, diagnostics, therapy. Because of the large
number of publications, systematic reviews and – where available – meta-analyses of ran-
domized controlled studies were selected. These were identified and subsequently linked
by content related criteria. If a minimum of 3 authors found an article relevant it was
included in the review.
Definition
In addition to quantifiable and reproducible traits, such as the ejaculatory latency time and
the personal mental trauma of one or both partners should be taken into consideration.
Premature ejaculation is mostly defined as a deviation from the normal length of intravaginal
ejaculatory latency time (IELT). This is the time from penetration to ejaculation. According
to Masters and Johnson, who formulated one of the first definitions in the 1970s, premature
ejaculation is the inability to delay the moment of ejaculation long enough so that the women
reaches orgasm in 50% of sexual encounters (3). Control over the moment of ejaculation
Urologische Gemeinschaftspraxis Remscheid, Kooperationspraxis der Klinik für Urologie und Kinderurologie, Klinikum Wuppertal,Universität Witten/Herdecke: Dr. med. Mathers, FEBU; Institut für Männergesundheit – Klinik und Poliklinik für Urologie, Univer-sitäts-Klinikum, Hamburg-Eppendorf: Dr. med. Schmitges, Prof. Dr. med. Sommer; Klinik für Urologie, Andrologie und Kinderuro-logie am Klinikum Weiden: Prof. Dr. med. Klotz, MPH Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de Definition der Ejaculatio praecox*
Source Definition
Persistent or repeated ejaculation with minimal sexualstimulation before or shortly after penetration and before theperson desired this. This state of affairs must cause noticeablemental trauma or interpersonal difficulties.
An inability to control ejaculation sufficiently, so that both partners enjoy the sexual act, because ejaculation occurs before or very shortly after starting intercourse (if a time limit is required, within 15 s) or because ejaculation occurs in the absence of an erection sufficient for intercourse.
The problem is not due to prolonged sexual abstinence.
An inability to control ejaculation for a sufficient time spanbefore vaginal penetration. This does not result in impairedfertility if intravaginal ejaculation occurs.
Ejaculation that occurs earlier than desired, either before or shortly after penetration, and which results in mental trauma for one or both partners.
* From (4, 5, 6, e2); AUA, American Urological Association; Estimated intravaginal ejaculatory latency time (IELT) of women and men
in different countries
Country (n = m/w)
Estimated IELT
Estimated IELT
for men (mins)
for women (mins)
and sexual satisfaction of the man and woman are possible components and are included inthe standard classification systems and guidelines of large urological organizations (4, 5).
Definitions of premature ejaculation in the Diagnostic and Statistical Manual of MentalDisorders, 4th edition (DSM-IV), International Classification of Diseases (ICD-10), andothers generally mention 3 central aspects (e1, e2): ❃ Shortened intravaginal ejaculatory latency time ❃ Loss of deliberate control of ejaculation ❃ Mental trauma in man or woman.
The suffering of the partner is mentioned only in DSM-IV and the guidelines of the American Urological Association (AUA) (table 1).
The sensation of what is "normal" varies and is highly subjective. The average time from penetration to ejaculation perceived as normal is 7 to 14 min and shows geographicalvariations. Women mostly estimate the time as slightly shorter (table 2) (6). Waldinger et al. found a median IELT of 5.4 min (diagram 1) in 491 men from 4 European countries and the United States (7). Analyzed by country, age, circumcision status, and useof condoms, the IELT was significantly shorter in older men (>51 years) and in men ofTurkish origin; sexual intercourse took place a median of 8 times per month in all subgroups(7). If the 0.5th and 2.5th percentile are chosen to define the disorder, the resulting range is0.9 to 1.3 min. Questionnaires can be used as an instrument for standardized psychometricrecording. Validated questionnaires are the IPE (index of premature ejaculation) (8) and theArab IPE (e3). The IPE comprises 10 items to describe sexual satisfaction, ejaculatory control,and mental trauma. The partner's sexual satisfaction is not included. In combination with Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de the time measurements of the IELT, two tools are therefore available to capture the pathologyof premature ejaculation. Questionnaire and time measurements do not reflect realconditions – in practice, personal mental trauma is crucial.
In the Second International Consultation on Erectile and Sexual Dysfunction (e4), "early ejaculation" or "rapid ejaculation" are suggested as replacement terms for "prematureejaculation." Another possible term might be "premature orgasm", because ejaculation isnot impaired; the problem is that the orgasm reflex is triggered too early. In addition to theexclusively premature orgasm, another type of orgasm could be differentiated that isassociated with erectile dysfunction. The secondary form occurs as a result of erectiledysfunction or reduction in sexual appetence. Prevalence
In the Global Study of Sexual Attitudes and Behaviours (GSSAB) (1, 2), the frequency of
premature ejaculation was investigated. This study included 27 500 men and women aged
40 to 80 worldwide. It is regarded as the largest epidemiological study of sexuality and its
dysfunctions. The GSSAB reported prevalence rates of up to 30%. Geographical differences
should be considered in the sociocultural context of the different countries. In selected
patients, prevalence rates of far higher than 50% were found (e5, e6).
Geographical and regional differences
In the GSSAB, premature ejaculation is the most common sexual dysfunction; its prevalence
is highest in Asia, Central America, and South America (diagram 2) (2). The explanation
for the high prevalence rates is the importance placed on female sexuality in these societies
(9, 10). In spite of patriarchal social structures and low described sexual activity (9), East
Asia has the Tantric and Taoist philosophies as its cultural or ideological foundation. In
their sexual traditions, the female organism is their central element (10). Coupled with this
is the perception among men that ejaculation that happens too early is a problem. The
coexistence of premature ejaculation and female anorgasmia supports this observation
(diagram 2).
Other factors
Erectile dysfunction can be regarded as a comorbidity, cause, or effect or premature ejaculation.
An association of premature ejaculation with low educational attainment has also been
described (2). Men without academic qualifications in Central America and South America
and in the Middle East are at doubly the risk of developing premature ejaculation. In the
Middle East, a difficult financial situation seems to have a negative influence (2). Irregular
sexual intercourse can lead to premature ejaculation, as is confirmed by the GSSAB.
Etiology and risk factors
Psychogenic and organic components can have a role in the etiology of premature ejaculation.
Anxiety disorders can have a key role in its development (11). A causal connection between
fear and male sexual dysfunction has not been confirmed to date. Whether anxiety disorders
are the sequelae or cause of premature ejaculation is not clear (12). The fear of premature
orgasm can reduce a couple's sexual pleasure (3, 8, 9). There are further psychological risk
factors that are associated with premature ejaculation. The most commonly named is sexual
inexperience, scarce sexual activity, and fearfulness (3). Organ related risk factors include
urinary tract infections and diabetes mellitus (e7). The side effects of some medical drugs –
for example, opiates and sympathomimetics – can result in premature ejaculation (e8). The
most common comorbidity, at up to 30%, is erectile dysfunction (13, 14). This should be
treated as a priority.
The role of serotonin in the ejaculatory process
In addition to hormones, several neurotransmitters influence sexual activity and the ejaculatory
process. A raised serotonin concentration in the brain in humans and rats raises the threshold
to ejaculation (e9). The impairment of male sexuality was ascribed to serotonergic neurons
of the medial raphe nuclei, whose inhibitory function is also responsible for the refractory
period between ejaculations (e10). Non-selective activation of serotonin receptors results
in dose dependent prolongation of the ejaculatory latency period up to anejaculation (15).
Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de DIAGRAM 1
average ejaculatorylatency time on 491couples in Europeand the UnitedStates. Adaptedfrom: Waldinger etal.: A multinational population survey ofintravaginal ejacu-lation latency time;adapted to (7) DIAGRAM 2
premature ejacu-lation in 7 regions.
Participants wereasked whether inthe preceding 12months, orgasmhad been reachedtoo rapidly for atleast 2 months.
Adapted from:Laumann et al.:Sexual problemsamong women andmen aged 40–80 y:prevalence andcorrelates identifiedin the Global Studyof Sexual Attitudesand Behaviorsadapted to (2) Diagnostics
Diagnosis is problematic. For clinical practice, qualitative and quantitative features have
been developed, which are not fully established. Only some men with premature ejaculation
receive medical help (16). Most men with sexual disorders would welcome talking to a doctor,
but only a small proportion is willing to initiate the conversation themselves (16, e11).
The GSSAB study showed that only 18% of men with a sexual problem had received medical advice (1). According to another study, only 1% of men aged above 40 years reported having received medical advice about their premature ejaculation, although theyhad told the treating physician about their problem (1). Similar results emerged from a large,anonymous, multinational internet study (17). It may be assumed that fewer patients receiveadvice for premature ejaculation than for erectile dysfunction (18). A detailed sexual history is of the utmost importance; this should include questions about sexual experiences,sexual development, and avoidance strategies already deployed. The extent to which the fear of premature orgasm impairs sexual pleasure should also be investigated (16). The history is part of the therapeutic conception because it provides a setting in which it is safeto admit whether the orgasm is associated with negative emotions.
If the time between insertion of the penis and ejaculation is less than 2 min as a rule, the definition of the pathology premature ejaculation is met (7). In clinical practice, prematureejaculation is diagnosed especially when the deliberate control of ejaculation fails and therelationship suffers as a result.
Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de Therapy
❃ Strengthen the man's physical sensitivity
❃ Psychotherapy/sexual therapy❃ Drug treatment – Local: lidocaine, prilocaine– Systemic: antidepressants: clomipramine, selective serotonin reuptake inhibitors (fluoxetine, sertraline,paroxetine, and dapoxetine) and phosphodiesterase-5inhibitors (sildenafil, vardenafil, tadalafil) DIAGRAM 3
the ejaculatoryreflex is interruptedby applying pressurein the frenulum areawith the tip of thethumb. The figureshows the use ofthe squeezetechnique with thehelp of a partner Therapy
Among underlying physical causes for premature ejaculation, psychoreactive elements
play a central part. Drug treatment targets the symptoms. Psychotherapeutically,
established behavioral therapies should be used (3, e11, e13). If possible, the partner
should be included.
For couple therapy, it is helpful if the patient is in a steady relationship, if the sexual problems are experienced as a central obstacle to a satisfying relationship, and if bothpartners are interested in the treatment. Approaching the problem together can even beenough to bring about the desired result in some cases and supports all subsequent measures.
This may help reduce the pressure for success – for example, by recommending sexualactivity without actual intercourse as a first step.
Controlled studies exist for all forms of therapy (box 1). The different study designs, however, hinder the interpretation of drug treatments that are given in accordance with theAUA guidelines of 2004 (e15). An exception is dapoxetine, as controlled studies have beenpublished only since 2004 and have a higher level of evidence; only very few studies covervardenafil and tadalafil. For some men, a preceding orgasm is helpful in delaying ejaculation. In some cases, sex therapy is an option to increase a man's sensitivity to the moment of ejaculation. The menaffected can learn through different techniques to experience as well as influence theprocess up to the point that they perceive as inevitable. The stop-start method (e13) and the Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de squeeze method recommended by Masters and Johnson (3) have proved successful intreatment, but even these are not uncontroversial. In the literature, most studies of premature ejaculation are neither prospective, randomized, controlled, blinded, nor quantified by IELT measurement and therefore do not meet thestrict criteria of evidence based studies (e14). Small cohort studies of patients without longterm follow-up exist (e14). An AUA committee complied guidelines in 2004, which wereaccepted by a consensus (e15). Stop-start method
This method aims to teach men to experience their own sexual arousal more clearly and
control it. In a first step, the man masturbates and then stops masturbating shortly before the
critical threshold, the point of no return. Further stimulation is avoided (stop signal) until
the patient has returned to a notably lower level of arousal. The then sexual stimulus is
renewed. The patient repeats the stop-and-start steps until he manages a certain degree of
control over his arousal (e13).
Squeeze method
The squeeze method is a modified stop-start exercise and aims to teach the man to experience
his arousal consciously by means of sensuality training. Afterwards he learns to realize the
moment at which ejaculation is imminent more precisely and in a further step, he learns to
influence this. By applying pressure with the tip of the thumb to the frenulum area, the
ejaculatory reflex is interrupted (diagram 3) (3). In optimal circumstances, the exercises
should be used in a relaxed atmosphere in the setting of couple therapy.
Masters and Johnson (3) in 1970 reported on 186 men who were treated with different behavioral approaches, including the squeeze technique. The success rate immediatelyafter therapy was 90%. Other working groups did not achieve such high rates (e12).
Hawton et al (e12) reported success rates of 64% immediately after behavioral therapies.
All long term reports confirm, however, that after therapy has concluded the problem ofpremature ejaculation has a tendency to resurface (19).
Drug therapy
In cases where psychotherapy has been insufficiently successful or not had any success at
all, several drugs can be administered.
Local anesthetics (such as lidocaine or prilocaine) are applied to the glans and reduce the excitability of the penis (e16). The effect usually sets in after about 20 min, but during ❃ Premature ejaculation is the most common problem in sexual function in men and is subject to strong culturalinfluences.
❃ Premature ejaculation is defined as a shortened intravaginal ejaculatory latency time, the loss ofdeliberate ejaculation control, and it is characterized bypersonal mental trauma of those affected.
❃ Diagnostics include a thorough sexual history, eliciting the extent of suffering mental trauma, and if requiredthe couple's dynamic and importance of sexuality.
❃ Psychotherapeutically, established therapies with different approaches from the armamentarium of sexualtherapies are used – the stop-start method and thesqueeze method after Masters and Johnson.
❃ Drug treatments include local anesthetics, antidepressants such as clomipramine and SSRIs, and PDE-5 inhibitors.
Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de Short case report
A 67 year old, married, successful businessman, whose hypertension has beenwell controlled for years, reports having experienced premature ejaculation.
Recently, sexual intercourse has been possible at most once a month, in a"quickie" fashion, if his partner stimulates him maximally; he then ejaculates inseconds. The wife has been sympathetic and does not think that sex is the mostimportant thing in life.
Relevant findingsNo findings on abdominal, genital, and rectal examination on physical examination,international index for erectile function (IIEF): 15 points (normal >25 points),RR 140/95 mm Hg, testosterone, prolactin, full blood count, thyroid stimulatinghormone, and blood glucose all in the normal range.
MethodsSexual therapy for the couple was recommended so that both partners learnt toexpress their desires. In parallel, a controlled attempt was made with PDE-5inhibitors at a medium dosage because of suspected secondary prematureejaculation. The cost problems were discussed with the patient.
VerlaufSex therapy over 3 months improved both partners' ability to articulate their sexualdesires. Erections improved in quality thanks to PDE-5 inhibitor treatment, and themedication is required only occasionally. The premature ejaculation improvedthroughout the couple therapy, so that the patient does not experience a relatedmental trauma.
intercourse, the partner's sensations may also become impaired. In double blinded, randomized,placebo controlled studies, IELT of longer than 5 min have been reported, as has greatly improved patient satisfaction (20, e17, e18). All oral drug therapies are off label, and the dosages differ from those given in licensed indications. Psychopharmaceuticals such as clomipramine and selective serotonin reuptake inhibitors (SSRIs)-such as fluoxetine, sertraline, or paroxetine – should be taken several hours beforesexual intercourse, so as to delay the time to ejaculation. Paroxetine is most efficacious(21). According to a prospective, double blinded, randomized, crossover study, all drugsmentioned prolong the IELT significantly (22). These drugs and the local anestheticsmentioned earlier were therefore included as therapeutic options in US guidelines (e15).
Dapoxetine is still going through the licensing process; its effect onset is rapid and its halflife is short (23).
In men who took the drug as needed, ejaculation was delayed significantly, by 3 min, in a randomized, double blinded, placebo controlled, phase 3 study (23). The study included2614 men who took either 30 mg or 60 mg dapoxetine in the treatment group.
Since 2001, studies have become available that investigated treatment for premature ejaculation with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, and more recentlyalso vardenafil and tadalafil), either alone or in combination with SSRIs. Most of thesestudies are, however, not double blinded and placebo controlled, and often the IELT wasnot measured (24). This limits the study conclusions with regard to efficacy andcomparability. Salonia et al, in a prospective study, compared the efficacy of paroxetinealone or in combination with sildenafil in 80 potent patients with premature ejaculation(25). The combination of paroxetine and sildenafil improved the IELT significant to morethan 5 min, compared with paroxetine alone (25). Results from other studies are equallyencouraging (22, 23, 24). The AUA guidelines mention only sildenafil (5). Individualstudies of vardenafil and tadalafil were published only after these guidelines in 2004.
Because of their low side effect profile and the fact that they can be taken when needed,PDE-5 inhibitors may be used to treat premature ejaculation, especially if the patient alsohas erectile dysfunction.
Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de Drug treatment cannot cure premature ejaculation; the problem continues to exist after the drugs have been stopped. Because of possible negative side effects, they should thereforebe used only as a measure of last resort.
Conclusions
Premature ejaculation is the commonest sexual disorder in men. Patients do not address
their problem often enough in the setting of a medical consultation. In clinical practice, a
diagnosis can be made by taking a targeted sexual history. Currently, no causal treatment is
known. Some therapies are promising. In addition to psychotherapeutic and behavioral
measures, antidepressants such as SSRIs, and phosphodiesterase-5 inhibitors have been
used successfully (box 2). Suitable treatment improves the patient's quality of life and often
has a positive effect on the relationship (short case report).
Conflict of Interest Statement
Dr Schmitges receives financial support from Bayer-Schering. Professor Sommer receives financial support from Bayer-Schering
and Pfizer. Dr Mathers and Professor Klotz declare that no conflict of interest exists according to the Guidelines of the International
Committee of Medical Journal Editors.
Manuscript received on 9 March 2007, revised version accepted on 22 October 2007.
Translated from the original German by Dr Birte Twisselmann.
REFERENCES
For e-references please refer to the additional references listed below.
1. Carson CC, Glasser DB, Laumann EO, West SL, Rosen RC: Prevalence and correlates of premature ejaculation among men aged 40 years and older: A United States nationwide population-based study. J Urol 2003; 169(Suppl 4): 321.
2. Laumann EO, Nicolosi A, Glasser DB et al.: Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17: 39–57.
3. Masters WH, Johnson VE: Human sexual inadequacy. Boston: Little Brown 1970.
4. Colpi G, Weidner W, Jungwirth A et al.: EAU guidelines on ejaculatory dysfunction. Eur Urol 2004; 46: 555–8.
5. Montague DK, Jarow J, Broderick GA et al.: AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004; 172: 290–4.
6. Sotomayer M: The burden of premature ejaculation: a patient’sperspective. J Sex Med 2005; 2: 110–4.
7. Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M: A multinational population survey of intravaginal ejaculation latency time. J Sex Med 2005; 2: 492–7.
8. Althof S, Rosen R, Symonds T, Mundayat R, May K, Abraham L: Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 2006; 3: 465–75.
9. Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO: Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40–80 years in the urban population of Asian countries. BJU Int 2005; 95: 609–14.
10. Francoeur RT: Sexuality and spirituality: the relevance of eastern traditions. SIECUS Rep 1992; 20: 1–8.
11. Jannini EA, Lenzi A: Epidemiology of premature ejaculation. Curr Opin Urol 2005; 15: 399–403.
12. Rowland DL, Slob AK: Premature ejaculation: psychophysiological considerations in theory, research, and treatment.
Annu Rev Sex Res 1997; 8 : 224–53.
13. Waldinger MD: Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int 2004; 14. Grenier G, Byers S: Operationalizing early or rapid ejaculation. J Sex Res 2001; 38: 369–78.
15. Waldinger MD, Hengeveld MW, Zwinderman AH: Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. BJU 1997; 79: 592–95.
16. Köhn F-M: Wenn Männer zu früh kommen. MMW-fortschr Med 2003; 46: 912–16.
17. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J: The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007; 51: 816–24.
18. Moreira ED: Help-seeking behavior for sexual problems: the Global Study of Sexual Attitudes and Behaviours.
19. Hawton K, Catalan J, Faff J: Sex therapy for erectile dysfunction: characteristics of couples, treatment outcome, and prognostic factors. Arch Sex Behav 1992; 21: 161–75.
20. Dinsmore WW, Hackett G, Goldmeier D et al.: Topical mixture for premature ejaculation (TEMPLE): a novel aerosol- delivery form of lidocain-prilocain for treating premature ejaculation. BJU Int 2007; 99: 369–75.
21. Waldinger MD: Premature ejaculation: definition und drug therapy. Drugs 2007; 67: 547–68.
22. Abdel-Hamid IA, El Naggar EA, El Gilany A-H: Assessments of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001; 13: 41–5.
23. Pryor JL, Althof SE, Steidle C et al.: Dapoxetine Study group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomized controlled trials. Lancet. 2006; 368:929–37.
Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de 24. Wang WF, Minhas S, Ralph DJ: Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation. Int J Androl 25. Salonia A, Maga T, Colombo R et al.: A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002; 168: 2486–9.
ADDITIONAL REFERENCES
e1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association. Ref Type: Statute. http://www.psych.org/public_info/libr_publ.
e2. World Health Organization. 1994. International classification of diseases and related health problems. Geneva: World Health Organization. Ref Type: Statute. http://www.who.int/classifications/apps/icd/icd10online/ e3. Arafa M, Shamloul R: Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire. Int J Impot Res 2006; 18: 534–8.
e4. Goldstein I: Primature to early ejaculation: a sampling of manuscripts regarding the most common male sexual dysfunction published in the IJIR: The Journal of Sexual Medicine. Int J Impot Res 2003; 15: 307–8.
e5. Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA: Prevalence of chronic prostatitis in men with premature ejaculation. Urology 2001; 58: 198–202.
e6. Aschka C, Himmel W, ittner E, Kochen MM: Sexual problems of male patients in familiy practice. J Fam Pract e7. El-Sakka AI: Premature ejaculation in non-insulin-dependent diabetic patients. Int J Androl 2003; 26: 329–34.
e8. Metz ME, Pryor JL: Premature ejaculation: a psychophysiological approach for assessment and management.
J Sex Marital Ther 2000; 26: 293–320.
e9. de Jong TR, Veening JG, Waldinger MD, Cools AR, Olivier B: Serotonin and the neurobiology of the ejaculatory threshold. Neurosci Biobehav Rev 2006; 30: 893–907.
e10. McMahon CG, Samali R: Pharmacological treatment of premature ejaculation. Curr Opin Urol 1999; 9: 553–5.
e11. Seftel AD, Althof SE: Premature ejaculation. In: Mulcahy JJ (ed.): Diagnosis and management of male sexual dysfunction. New York: Igaku-Shoin 1997, 196–203.
e12. Hawton K, Catalan J, Martin P, Faff J: Long-term outcome of sex therapy. Behav Res Ther 1986; 24: 665–75.
e13. Semans JH: Premature ejaculation: a new approach. South Med J 1956; 49: 353–8.
e14. Althof SE: Psychological treatment strategies for rapid ejaculation: rationale, practical aspect, and outcome.
e15. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID: AUA Erectile dysfunction guideline update panel. AUA guideline on the pharmacologic management of premature ejaculation.
J Urol 2004; 172: 290–4.
e16. Riley A, Segraves RT: Treatment of premature ejaculation. Int J Clin Pract 2006; 60: 694–7.
e17. Pirozzi Farrina F: Gli anestetica di contatto nel trattamento del-l´elacuazione prematura primitiva. It Androl 2000; e18. Busato W, Galindo CC: Topical anasthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU 2004; 93: 1018–21.
Corresponding author
Dr. med. Michael J. Mathers, FEBU
Fastenrathstr. 1
42853 Remscheid, Germany
[email protected]
Dtsch Arztebl 2007; 104(50): A 3475–80 ⏐ www.aerzteblatt.de

Source: http://www.msvgrupomedico.com/Introduction%20Into%20the%20Diagnostics.pdf